Physicochemical characterization of chitosan-hyaluronan-coated solid lipid nanoparticles for the targeted delivery of paclitaxel: a proof-of-concept study in breast cancer cells.
OBJECTIVE
To investigate the potential of modified solid lipid nanoparticles (SLN) for the delivery of paclitaxel (PAX).


METHODS
SLN loaded with PAX were prepared via modified high-pressure hot homogenization. Formulation parameters were optimized to obtain a high-quality delivery system. SLN cores were coated, layer-by-layer, with a chitosan and hyaluronan (HA) shell. Selectivity toward HA receptors was tested in a breast cancer cell line, MCF-7.


RESULTS
Stable and reproducible nano-sized and negatively charged nanoparticles resulted. Findings reveal that chitosan-HA-coated SLN facilitated the targeting, cellular uptake and the time-/dose-controlled delivery and release of PAX, enhancing intrinsic chemotherapeutic activities.


CONCLUSIONS
SLN are suitable carrier candidates for nano-oncology given their localized, and potent cytotoxic potential overcoming multidrug-resistant cancer cells.
Biomaterials & Tissue Engineering Research Group (BioMAT'X), Centro de Investigación Biomédica, Universidad de los Andes, Monseñor Álvaro del Portillo 12.455, Las Condes, Santiago, Chile.|Programa de Mejoramiento Institucional (PMI), I+D+i, Dirección de Innovación, Universidad de los Andes, Monseñor Álvaro del Portillo 12.455, Las Condes, Santiago, Chile.
Javier
J
Campos
Programa de Mejoramiento Institucional (PMI), I+D+i, Dirección de Innovación, Universidad de los Andes, Monseñor Álvaro del Portillo 12.455, Las Condes, Santiago, Chile.|Laboratorio Biología de la Reproducción, Centro de Investigación Biomédica, Universidad de los Andes, Monseñor Álvaro del Portillo 12.455, Las Condes, Santiago, Chile.
Manuel
M
Varas-Godoy
Biomaterials & Tissue Engineering Research Group (BioMAT'X), Centro de Investigación Biomédica, Universidad de los Andes, Monseñor Álvaro del Portillo 12.455, Las Condes, Santiago, Chile.|Programa de Mejoramiento Institucional (PMI), I+D+i, Dirección de Innovación, Universidad de los Andes, Monseñor Álvaro del Portillo 12.455, Las Condes, Santiago, Chile.|Faculty of Dentistry, Universidad de los Andes, Monseñor Álvaro del Portillo 12.455, Las Condes, Santiago, Chile.
Ziyad Samir
ZS
Haidar
D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002470:Cell Survival / Q000187:drug effects; D048271:Chitosan / Q000737:chemistry; D016503:Drug Delivery Systems; D004355:Drug Stability; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000737:chemistry; D008055:Lipids / Q000008:administration & dosage / Q000737:chemistry; D061986:MCF-7 Cells; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry; D017239:Paclitaxel / Q000008:administration & dosage* / Q000737:chemistry
D008055:Lipids; D006820:Hyaluronic Acid; D048271:Chitosan; D017239:Paclitaxel
chitosan; drug delivery; hyaluronan; layer-by-layer; multidrug resistance; nanoncology; paclitaxel; solid lipid nanoparticles